Testing for Human Immunodeficiency Virus Among Cancer Survivors Under Age 65 in the United States

Jun Li, MD, PhD, MPH; Trevor D. Thompson, BS; Eric Tai, MD, MPH; Guixiang Zhao, MD, PhD; Alexandra M. Oster, MD, MPH

Abstract

Introduction
Knowing the human immunodeficiency virus (HIV) serostatus of patients at the time of cancer diagnosis or cancer recurrence is prerequisite to coordinating HIV and cancer treatments and improving treatment outcomes. However, there are no published data about HIV testing among cancer survivors in the United States. We sought to provide estimates of the proportion of cancer survivors tested for HIV and to characterize factors associated with having had HIV testing.

Methods
We used data from the 2009 Behavioral Risk Factor Surveillance System to calculate the proportion of cancer survivors under age 65 who had undergone HIV testing, by demographic and health-related factors and by state. Adjusted proportion estimates were calculated by multivariable logistic regression.

Results
Only 41% of cancer survivors in the United States under the age of 65 reported ever having had an HIV test. The highest proportion of survivors tested was among patients aged 25 to 34 years (72.2%), non-Hispanic blacks (59.5%), and cervical cancer survivors (51.2%). The proportion tested was highest in the District of Columbia (68.3%) and lowest in Nebraska (24.1%). Multivariable analysis showed that factors associated with HIV testing included being non-Hispanic black or Hispanic, being younger, having higher education, not being married or living with a partner, not being disabled, and having medical cost concerns. Having an AIDS-related cancer was associated with HIV testing only among females.

Conclusion
The proportions of HIV testing varied substantially by demographic and health-related factors and by state. Our study points to the need for public health interventions to promote HIV testing among cancer survivors.

Introduction
In 2010, about 50,000 new human immunodeficiency virus (HIV) infections occurred in the United States, and more than 1.1 million people were living with HIV infection (1,2). About 16% of HIV infections go undetected (2). Since 2006, the Centers for Disease Control and Prevention (CDC) has recommended HIV testing as a routine part of medical care for all persons aged 13 to 64 years (3). Compared with the general population, people with HIV infection have increased cancer risks; Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer are AIDS-related cancers (4,5). Because of co-infections with hepatitis B and C and Epstein-Barr virus, HIV-infected people also have elevated risks for non-AIDS–related cancers, such as liver cancer and Hodgkin disease (6).

Driven by improvements in early detection and treatment, cancer survival rates have increased substantially in the past 30 years (7). By 2007, nearly 12 million US cancer survivors were living, and the number is projected to reach about 18 million by 2022 (8,9). Given the high prevalence of both cancer and HIV infection and the natural linkage between the two, occurrence of HIV infection in cancer survivors is not rare. Patel et al reported that for HIV-infected persons, having AIDS-related cancers, a lower cluster of differentiation (CD4) cell count, and high viral load at cancer dia-
agnosis were positively associated with poor 5-year survival (10). Undiagnosed HIV infection among cancer patients may contribute to poor cancer treatment outcomes and delay timely HIV care and treatment, resulting in increased risks for death (11). Identification of cancer survivors who have never been tested for HIV infection can reduce that risk.

To our knowledge, little is known about HIV testing among cancer survivors (11). This study’s objective was to describe the proportion of cancer survivors tested for HIV by demographic and health-related variables, to provide state-specific estimates of HIV testing, and to characterize factors associated with HIV testing.

Methods

Data source

Data for this analysis came from the 2009 Behavioral Risk Factor Surveillance System (BRFSS), an ongoing, state-based, random-digit–dialed telephone survey of the noninstitutionalized US civilian population aged over 18 years. The BRFSS (www.cdc.gov/BRFSS/) collects information on diseases, health-related behaviors, preventive health practices, and access to health care in the United States. In 2009, BRFSS was conducted in all 50 states, the District of Columbia, Puerto Rico, the US Virgin Islands, and Guam. The median response rate for the 2009 BRFSS was 52.5%, and the median cooperation rate was 75% (12).

Study subjects and variables

In accordance with CDC’s recommended HIV testing criteria (3), we restricted our analysis to persons who reported a history of cancer, were aged 18 to 64 years, and fell within the age range of the BRFSS survey.

Cancer-related variables

Respondents were asked whether they had ever been told by a doctor, nurse, or other health care professional that they had cancer. Respondents who answered yes were asked how many different types of cancer they had had, the age at which they were first told that they had cancer, and for respondents who reported having had more than one type of cancer, which type of cancer had most recently been diagnosed. Respondents who were unsure about their history of cancer or who refused to answer the question were excluded from the analysis.

For cancer survivors, the duration of cancer survivorship was calculated by using the respondent’s current age and the age at first cancer diagnosis. Cancer types were grouped as AIDS-related cancers (non-Hodgkin lymphoma and cervical cancer) and non-AIDS-related cancers (ie, prostate, female breast, colon, and liver; melanoma and other skin cancers; and other non-AIDS–related cancers) (5). Information on Kaposi sarcoma was not available from the BRFSS questionnaires, so we were unable to include it among AIDS-related cancers.

HIV-related variables

Respondents were also asked whether they had ever been tested for HIV. Persons were considered to have recent HIV risk behaviors if they answered yes to any of the following questions regarding the past year: 1) Have you used intravenous drugs? 2) Have you been treated for a sexually transmitted disease? 3) Have you given or received money or drugs in exchange for sex? and 4) Have you had anal sex without a condom?

Other variables

We examined the following factors, which were potentially related to HIV testing: demographics (sex, race/ethnicity, age at interview, education, and marital status), psychological status (emotional support and life satisfaction), health care access (insurance status, being concerned about medical costs in the past 12 months, and having a routine checkup in the past 12 months), and disability status, which was defined as being limited in any way in any activities because of physical, mental, or emotional problems.

Statistical analyses

We examined HIV testing among cancer survivors by stratifying by the aforementioned variables. Proportions tested for HIV were age-standardized to the age distribution of cancer survivors in the 2009 BRFSS. Ninety-five percent confidence intervals around the estimated proportions were calculated on the basis of a logit transformation. Statistical testing for differences in age-standardized measures was performed using general linear contrasts. We also calculated estimated proportions tested for each of the 50 states and the District of Columbia. A multivariable logistic regression model was fitted to determine the adjusted relationships between HIV testing and the aforementioned demographic and health-related variables among cancer survivors in the United States. Age and time since cancer diagnosis were treated as continuous variables in the model and transformed by using restricted cubic spline functions to allow for nonlinearity. The adjusted associations between discrete variables and HIV testing are presented as predictive margins. The predictive margin for a specific group represents the average predicted response if everyone in the sample had been in that group. Because AIDS-related cancer types vary for men and women, we included a term describing sex by AIDS-related cancer interaction in the model to assess whether the effect varied by sex. Statistical testing for the age-adjusted and multivariable analyses was based on the Wald F test. We performed the
analysis by using SAS version 9.3 (SAS Institute Inc) with SU-DAAN version 11.0.0 (RTI International) along with the RMS version 3.6–3 and survey packages version 3.28–2, components of R version 3.0.1 (R Foundation for Statistical Computing) to account for the complex sampling design and to allow for weighted estimates. Significance was set at $P < .05$.

**Results**

Of 407,402 persons interviewed during 2009 who answered the questions about cancer history, 59,173 reported a history of cancer. Of these, 24,485 were aged 18 to 64 years and were included in our analysis. Most cancer survivors were women (62.3%), non-Hispanic white (83.5%), aged 45 to 64 years (74.6%), and had health insurance (89.5%). About 13% of cancer survivors had AIDS-related cancers: 11.5% had cervical cancer and 1.9% non-Hodgkin lymphoma. Approximately 3% of cancer survivors reported at least 1 HIV risk behavior in the past year.

Of cancer survivors aged 18 to 64 years, 40.8% reported having ever had an HIV test (Table 1). The proportion who reported HIV testing varied significantly by race/ethnicity, age, education, cancer type, time since cancer diagnosis, and HIV risk behaviors. Within these respective categories, those most likely to have been tested included non-Hispanic blacks (59.5%), patients aged 25 to 34 years (72.2%), patients with less than a high school education (45.0%), cervical cancer survivors (51.2%), survivors 5 to 9 years post cancer diagnosis (42.9%), and those who reported engaging in at least 1 HIV risk behavior in the past year (58.0%). Measures of emotional support, life satisfaction, employment status, marital status, disability status, health insurance, and medical cost concern also were significantly associated with HIV testing. History of HIV testing varied significantly by state, ranging from 68.3% in the District of Columbia to 24.1% in Nebraska (Table 2). Among all states, the District of Columbia (68.3), Maryland (50.6%) and California (48.7%) had the highest proportions of cancer survivors who reported having been tested for HIV.

The multivariable logistic regression analysis (Table 3) revealed that women with an AIDS-related cancer, persons who had ever had a disability, and patients with medical cost concern were more likely to report having had an HIV test than men with cancer and women with non-AIDS–related cancer, those who did not have a disability or those who did not have medical cost concerns. Other significant findings included higher prevalences of testing among non-Hispanic blacks and Hispanics, patients with at least some college education, and patients who were not currently married or living with a partner. After adjusting for all variables, health insurance, emotional support, life satisfaction, employment status, and HIV risk behaviors were no longer significantly associated with HIV testing. There was a significant nonlinear association between age and HIV testing. Increasing age was significantly associated with a decline in HIV testing above age 35 (Figure 1). HIV testing prevalence tended to be slightly higher with increasing time since diagnosis up to around 10 years with slightly lower testing with increasing years since diagnosis beyond 20 years (Figure 2). However, this relationship was not significant ($P = .07$).
Discussion

Our study, based on the largest telephone survey of adults in the United States, found that only 41% of US cancer survivors under age 65 in 2009 had ever had an HIV test. The likelihood of having had HIV testing varied markedly by state. Factors associated with HIV testing included being non-Hispanic black or Hispanic, younger age, having higher education, not being married or living with a partner, being disabled, and having medical cost concerns. Having an AIDS-related cancer was associated with HIV testing only among women.

Although information on the proportion tested for HIV is lacking for cancer survivors, it has been widely reported for the US general population. In 2013, CDC reported, on the basis of the National Health Interview Survey (NHIS), that the percentage of adults who had ever been tested for HIV significantly increased from 36.6% in 2000 to 45.0% in 2010 (13). Similar to what we have observed among cancer survivors, NHIS analyses showed that among the general population, non-Hispanic blacks, people aged 25 to 34 years, and people with a reported risk for HIV infection had the highest proportion of HIV testing (13). A British study examined HIV testing among cancer patients in a clinic where HIV testing was recommended for all lymphoma patients (14). This study reported that only 59% of 113 lymphoma patients underwent an HIV test after their cancer diagnosis, and a high prevalence of HIV co-infection (8.0%) was observed (14). In 2013, the US Preventive Services Task Force also recommended that clinicians screen adolescents and adults aged 15 to 65 years who were at average risk for HIV infection (15). The low percentage of HIV testing reported by our study emphasizes the need for more efforts to promote HIV testing among cancer survivors. Our study may serve as a baseline measure to monitor changes in HIV testing among cancer survivors.

Compared with the overall population, adolescents and young adults are disproportionately affected by HIV (3). This finding may partially account for the decline in HIV testing with age, as suggested by our study. However, among persons living with a diagnosed HIV infection, the percentage aged 50 years or older increased from 28.6% in 2007 to 32.7% in 2009 (1). One possible explanation is that HIV testing increased over time among this older population (13). The positive associations between HIV testing and disabilities as identified in our study were consistent with a 2002 NHIS study among the general population (16). That study revealed that adults with physical and mental disability were more likely to report having had an HIV test than nondisabled adults (16). One explanation for the greater likelihood of HIV testing among physically and mentally disabled adults was their increased risk of rape and sexual abuse and a higher rate of participation in HIV risk behaviors (16).

Our study shows that about 60% of US cancer survivors under age 65 have never had an HIV test. Although non-Hodgkin lymphoma and cervical cancers are AIDS-related cancers, almost half of patients with these cancers had never been tested for HIV. The nontargeted “opt-out” HIV testing (the test will be performed unless the patient declines) in all health care settings, recommended by CDC in 2006, has not been widely implemented (11). This may, in part, contribute to the low reports of HIV testing among cancer survivors. Other contributing factors have not been reported in the literature. However, studies have shown that for the general population, fear, stigma, and discrimination associated with an HIV diagnosis; physicians’ attitudes; and the need for additional health care personnel and effort affect adoption of HIV testing (13,17,18). In addition, the cost or reimbursement of the cost for HIV testing are shared concerns of both patients and health care providers (19). In our study, we found that only 16.7% of cancer survivors reported having medical cost concerns, and cancer survivors who had medical cost concerns were more likely to have had an HIV test than cancer survivors who had no such concerns. In 2009, the Centers for Medicare and Medicaid Services allowed reimbursement for routine HIV testing (20). However, the changes in Medicare and Medicaid coverage may not have had a substantial effect on HIV testing in our study population because of the age limits of 18 to 64 years and the time the survey was conducted. One possible explanation is that medical cost concerns are a surrogate for having low income. Those who have low income may be perceived to be at higher risk for HIV by health care providers and, therefore, may be more likely to be tested. Additional research is warranted to further investigate this issue.

Separate written consent for HIV testing among nonpregnant adults is another well recognized barrier. Twenty states had laws or regulations that required separate written consent when CDC released its 2006 HIV testing recommendation (17). By 2008, 11 states, including California and Maryland, enacted new legislation or regulations to remove this barrier (17). Our findings that in 2009, the District of Columbia, Maryland, and California had the highest reports of HIV testing among all the states may be partially due to the absence of requirements for separate consent in these states. Removal of requirements for a separate written consent for HIV testing in every state would likely promote HIV testing and reduce variations among states.

Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer occur in excess in persons living with HIV (5). These cancers have been deemed AIDS-related conditions (5). Previous studies also
indicate that HIV-infected persons are at higher risk than the general population for several non-AIDS–related cancers, such as anal cancer, Hodgkin disease, liver cancer, lung cancer, melanoma, and colorectal cancer (21,22). Besides the advent of highly active antiretroviral therapy, which has prolonged survival of HIV-infected patients, other factors that may account for increased cancer risk are immunosuppression (23,24), co-infection with an oncogenic virus (25–27), and unhealthy behaviors such as smoking (28). Awareness of HIV status is important at the time of cancer diagnosis or cancer recurrence to avoid treatment-related complications from co-infection with HIV, drug interactions, potential effects of chemotherapy on the CD4 cell count, and HIV viral load (14). Early identification of patients with HIV infection would allow early implementation of HIV infection prevention and control measures to reduce hospital-acquired infections among patients and health care providers (29,30). Coordination of anticancer and anti-HIV therapies could improve treatment outcomes among HIV-infected adults newly diagnosed with cancer or with cancer recurrence. Additionally, by knowing patients’ HIV status, health care providers can identify cancer survivors who are at elevated risk for a secondary cancer and educate them about the need for cancer screenings.

Our study has several limitations. First, BRFSS data were self-reported and subject to recall bias. Recall bias may be responsible for the slightly higher prevalence of certain cancers when compared with a study that used cancer registry data (8). HIV testing history data were self-reported and may be subject to social desirability or recall biases. Opt-out testing may also contribute to recall biases. For instance, patients may not have explicitly consented, so they may have been unaware when they were tested. Because of the limitations of recall bias and self-report, this study may seriously underestimate actual HIV testing among cancer survivors. Second, we are not able to determine whether the testing occurred before, at the time of, or after their cancer diagnosis. Third, because the 2009 BRFSS sampled only respondents with a landline telephone, persons without a landline telephone were excluded from this study. Fourth, BRFSS is limited to noninstitutionalized US citizens; cancer survivors who lived in nursing homes, long-term care facilities, or hospice were excluded. Last, the low response rate of 52.2% in the 2009 survey may limit the generalizability of the results to all cancer survivors living in the United States.

In conclusion, in 2009 about 60% of US cancer survivors under age 65 had never had an HIV test. The proportion of HIV testing varied substantially by demographic and health-related factors and by state. Increasing the proportion of new HIV infections diagnosed before progression to AIDS is a Healthy People 2020 objective. One of the targets in the National HIV/AIDS Strategy is to increase the percentage of people who are living with HIV and know their serostatus from 79% to 90% by 2015. (13) Knowing the HIV serostatus at the time of cancer diagnosis or cancer recurrence is prerequisite to coordinating HIV and cancer treatments and improving treatment outcomes. Thus, our study points to the need for public health interventions to promote HIV testing among cancer survivors, especially among the demographic subgroups and states with a low proportion of HIV testing. With HIV testing, health care providers also can identify cancer survivors who are at elevated risk for a secondary cancer and educate them about the need for cancer screenings.

Acknowledgments

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Authors have no financial support or competing interest to declare.

Author Information

Corresponding Author: Jun Li, MD, PhD, MPH, Epidemiologist, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F76, Atlanta, GA 30341. Telephone: 770-488-3030. E-mail: ffa2@cdc.gov.

Author Affiliations: Trevor D. Thompson, Eric Tai, Guixiang Zhao, Alexandra M. Oster, Centers for Disease Control and Prevention, Atlanta, Georgia.

References

1. Estimated HIV incidence in the United States, 2007–2010. HIV surveillance supplemental report. Atlanta (GA): Centers for Disease Control and Prevention; 2012. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/#supplement. Accessed November 30, 2013.

2. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data — United States and 6 US dependent areas — 2011. HIV surveillance supplemental report. Atlanta (GA): Centers for Disease Control and Prevention; 2013. http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed January 31, 2014.

3. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55(RR-14):1–17.
4. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123(1):187–94.

5. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection among children aged 18 months to <13 years — United States, 2008. MMWR Recomm Rep 2008;57(RR-10):1–12.

6. Shielis MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009;52(5):611–22.

7. SEER Cancer Statistics Review. 1975–2010. Bethesda (MD): National Cancer Institute; 2012. http://seer.cancer.gov/csr/1975_2010/. Accessed July 5, 2013.

8. Centers for Disease Control and Prevention. Cancer survivors — United States, 2007. MMWR Morb Mortal Wkly Rep 2011;60(9):269–72.

9. de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013;22(4):561–70.

10. Patel P, Armon C, Chmiel JS, Brooks JT, Buchacz K, Wood K, et al. Factors associated with cancer incidence and with all-cause mortality after cancer diagnosis among human immunodeficiency virus–infected persons during the combination antiretroviral therapy era. Open Forum Infectious Disease; 2014. http://ofid.oxfordjournals.org/content/1/1/ofu012.abstract. Accessed August 20, 2014.

11. Chiao EY, Dezube BJ, Krown SE, Wachsmann W, Brock MV, Giordano TP, et al. Time for oncologists to opt in for routine opt-out HIV testing? JAMA 2010;304(3):334–9.

12. Behavioral Risk Factor Surveillance System summary data quality report. Atlanta (GA): Centers for Disease Control and Prevention; 2009. http://www.cdc.gov/brfss/annual_data/annual_2009.htm. Accessed July 11, 2013.

13. HIV testing trends in the United States. 2000–2011. Atlanta (GA): Centers for Disease Control and Prevention; 2013. http://www.cdc.gov/hiv/pdf/testing_trends.pdf. Accessed July 2, 2013.

14. Cave J, Edwards SG, Miller RF, Ardesha KM, Lee SM. Should we implement “opt-out” HIV testing for patients with lymphoma? Clin Med 2009;9(4):320–2.

15. Moyer VA. US Preventive Service Task Force. Screening for HIV: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159(1):51–60.

16. Neri SV, Bradley EH, Groce NE. Frequency of HIV testing among persons with disabilities: results from the National Health Interview Survey, 2002. AIDS Educ Prev 2007;19(6):545–54.

17. Bartlett JG, Branson BM, Fenton K, Haukchild BC, Miller V, Mayer KH. Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA 2008;300(8):945–51.

18. Burke RC, Sepkowitz KA, Bernstein KT, Karpati AM, Myers JE, Tsoi BW, et al. Why don’t physicians test for HIV? A review of the US literature. AIDS 2007;21(12):1617–24.

19. Schwartz S, Richards TA, Frank H, Wenzel C, Hsu LC, Chin CS, et al. Identifying barriers to HIV testing: personal and contextual factors associated with late HIV testing. AIDS Care 2011;23(7):892–900.

20. Medicare expands list of covered preventive services to include HIV screening tests. Washington (DC): US Department of Health and Human Services; 2009. http://www.medicare_expands_list_of_covered_preventive_services_to_incl hvor medicalwebtimes.com/read/ Accessed August 20, 2014.

21. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008;148(10):728–36.

22. Shielis MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103(9):753–62.

23. Bini EJ, Park J, Francois F. Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med 2006;166(15):1626–31.

24. Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285(13):1736–45.

25. Forastiere A, Koch W, Trottie A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345(26):1890–900.

26. Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17(5):477–83.

27. Wistuba II, Behrens C, Gazdar AF. Pathogenesis of non-AIDS–defining cancers: a review. AIDS Patient Care STDS 1999;13(7):415–26.

28. Todes, Gieryk SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010;14(4):824–35.

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
29. Centers for Disease Control and Prevention. Missed opportunities for earlier diagnosis of HIV infection — South Carolina, 1997–2005. MMWR Morb Mortal Wkly Rep 2006; 55(47):1269–72.

30. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis 2007;45(10):1369–74.
Table 1. Age-Standardized<sup>a</sup> Proportion of US Cancer Survivors Aged 18 to 64 Years<sup>b</sup> Tested for HIV, Behavioral Risk Factor Surveillance System, 2009

| Characteristics              | N<sup>c</sup> | % (95% CI)       | P Value |
|------------------------------|--------------|-----------------|---------|
| Total                        | 23,626       | 40.8 (39.7–42.0) | NA      |
| Sex                          |              |                 |         |
| Male                         | 7,180        | 41.6 (39.4–43.8) | .21     |
| Female                       | 16,446       | 40.0 (38.7–41.3) |         |
| Race/ethnicity               |              |                 |         |
| Non-Hispanic white           | 20,605       | 37.7 (36.6–38.9) | .001    |
| Non-Hispanic black           | 1,207        | 59.5 (54.7–64.1) |         |
| Hispanic                     | 839          | 52.3 (46.9–57.7) |         |
| Non-Hispanic other           | 764          | 48.3 (40.6–56.1) |         |
| Age, y                       |              |                 |         |
| 18–24                        | 148          | 52.4 (39.6–64.8) | <.001   |
| 25–34                        | 874          | 72.2 (66.7–77.1) |         |
| 35–44                        | 2,535        | 59.1 (55.7–62.4) |         |
| 45–54                        | 6,979        | 42.9 (40.8–45.0) |         |
| 55–64                        | 13,090       | 26.2 (24.9–27.6) |         |
| Education                    |              |                 |         |
| <High school graduate        | 1,382        | 45.0 (40.6–49.4) | <.001   |
| High school graduate         | 5,879        | 35.8 (33.6–38.0) |         |
| Some college                 | 6,971        | 43.9 (41.7–46.2) |         |
| College graduate             | 9,374        | 40.8 (39.0–42.6) |         |
| Employment                   |              |                 |         |
| Employed                     | 13,696       | 38.4 (37.0–39.9) | <.001   |
| Not employed                 | 9,886        | 44.9 (43.1–46.7) |         |
| Marital status               |              |                 |         |
| Married or living with a partner | 14,858   | 36.4 (35.1–37.8) | <.001   |
| Divorced, separated, or widowed | 6,547     | 53.6 (51.3–55.8) |         |
| Never married                | 2,150        | 54.7 (50.8–58.5) |         |
| Type of cancer               |              |                 |         |
| AIDS-related cancer          |              |                 |         |
| Cervical cancer              | 2,600        | 51.2 (47.9–54.5) | <.001   |
| Non-Hodgkin lymphoma         | 284          | 44.8 (34.7–55.4) |         |

Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.
<sup>a</sup> Results for all variables except age were age-standardized to the age distribution of cancer survivors in the 2009 BRFSS.
<sup>b</sup> 612 participants were excluded because of missing HIV status.
<sup>c</sup> Numbers may not add up to totals because of “don’t know,” “refused,” or missing responses.

(continued on next page)
Table 1. Age-Standardized Proportion of US Cancer Survivors Aged 18 to 64 Years Testing for HIV, Behavioral Risk Factor Surveillance System, 2009

| Characteristics                      | Nº   | % (95% CI)       | P Value |
|--------------------------------------|------|------------------|---------|
| **Non-AIDS–related cancer**          |      |                  |         |
| Prostate                             | 1,073| 47.3 (42.7–51.9) | <.001   |
| Female breast                        | 3,771| 37.3 (34.6–40.1) |         |
| Colon                                | 832  | 36.6 (30.7–42.9) |         |
| Melanoma                             | 2,407| 35.0 (31.8–38.5) |         |
| Other skin                           | 5,357| 36.7 (34.5–39.0) |         |
| Liver                                | 83   | 61.9 (48.3–73.9) |         |
| Other                                | 6,549| 42.7 (40.5–44.9) |         |
| **Time since cancer diagnosis, y**   |      |                  |         |
| 0–4                                  | 8,000| 38.7 (36.8–40.6) | .04     |
| 5–9                                  | 5,084| 42.9 (40.4–45.4) |         |
| 10–19                                | 5,537| 41.5 (39.3–43.8) |         |
| ≥20                                  | 4,473| 39.7 (36.3–43.1) |         |
| **Emotional support**                |      |                  |         |
| Always                               | 18,369| 39.1 (37.8–40.4) | <.001   |
| Sometimes                            | 3,197| 47.3 (44.2–50.4) |         |
| Rare or none                         | 1,909| 47.0 (43.3–50.8) |         |
| **Life satisfaction**                |      |                  | <.001   |
| Very satisfied                       | 10,125| 36.9 (35.2–38.6) |         |
| Satisfied                            | 11,339| 42.0 (40.4–43.7) |         |
| Dissatisfied                         | 1,531| 52.1 (48.1–56.0) |         |
| Very dissatisfied                    | 479  | 53.1 (46.2–59.8) |         |
| **Health insurance**                 |      |                  | .03     |
| Yes                                  | 21,239| 40.4 (39.2–41.7) |         |
| No                                   | 2,363 | 44.4 (41.1–47.7) |         |
| **Time since last checkup**          |      |                  | .24     |
| Within past year                     | 17,848| 41.3 (39.9–42.6) |         |
| 1 – <2 y                             | 2,681 | 38.7 (35.6–41.9) |         |
| 2 – <5 y                             | 1,421 | 40.8 (36.7–45.1) |         |
| ≥5 y                                 | 1,320 | 37.9 (33.8–42.2) |         |
| Never                                | 166  | 48.5 (36.8–60.3) |         |

Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.

a Results for all variables except age were age-standardized to the age distribution of cancer survivors in the 2009 BRFSS.

b 612 participants were excluded because of missing HIV status.

c Numbers may not add up to totals because of “don't know,” “refused,” or missing responses.
Table 1. Age-Standardized\textsuperscript{a} Proportion of US Cancer Survivors Aged 18 to 64 Years\textsuperscript{b} Tested for HIV, Behavioral Risk Factor Surveillance System, 2009

| Characteristics      | N\textsuperscript{c} | % (95% CI)          | P Value |
|----------------------|-----------------------|---------------------|---------|
|                      |                       |                     |         |
| Yes                  | 3,713                 | 48.5 (45.8–51.2)    | <.001   |
| No                   | 19,875                | 39.2 (37.9–40.5)    |         |
| Ever had disability  |                       |                     |         |
| Yes                  | 8,225                 | 49.9 (48.0–51.9)    | <.001   |
| No                   | 15,306                | 36.4 (35.1–37.8)    |         |
| HIV risk behaviors   |                       |                     |         |
| Yes                  | 520                   | 58.0 (51.0–64.7)    | <.001   |
| No                   | 23,069                | 40.5 (39.3–41.7)    |         |

Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.
\textsuperscript{a} Results for all variables except age were age-standardized to the age distribution of cancer survivors in the 2009 BRFSS.
\textsuperscript{b} 612 participants were excluded because of missing HIV status.
\textsuperscript{c} Numbers may not add up to totals because of “don't know,” “refused,” or missing responses.
## Table 2. Age-Standardized Proportion of HIV Tests Among Cancer Survivors Aged 18 to 64 Years, by State, Behavioral Risk Factor Surveillance System, 2009

| State               | N   | % (95% CI)       |
|---------------------|-----|------------------|
| Total               | 23,626 | 40.8 (39.7–42.0) |
| Alabama             | 382  | 44.6 (37.9–51.4) |
| Alaska              | 131  | 45.1 (35.3–55.4) |
| Arizona             | 327  | 38.8 (31.2–46.9) |
| Arkansas            | 210  | 37.4 (30.4–44.9) |
| California          | 794  | 48.7 (44.6–52.8) |
| Colorado            | 679  | 42.1 (37.5–46.7) |
| Connecticut         | 322  | 38.3 (32.2–44.8) |
| Delaware            | 240  | 44.7 (37.9–51.7) |
| District of Columbia| 189  | 68.3 (61.3–74.6) |
| Florida             | 762  | 46.5 (41.3–51.6) |
| Georgia             | 342  | 40.5 (34.7–46.5) |
| Hawaii              | 361  | 36.7 (30.4–43.5) |
| Idaho               | 330  | 30.0 (24.8–35.8) |
| Illinois            | 286  | 34.4 (27.7–41.8) |
| Indiana             | 525  | 39.5 (34.3–45.0) |
| Iowa                | 296  | 30.7 (24.1–38.2) |
| Kansas              | 1,064 | 34.2 (31.1–37.3) |
| Kentucky            | 629  | 36.2 (30.4–42.3) |
| Louisiana           | 463  | 46.4 (40.8–52.0) |
| Maine               | 501  | 38.1 (33.4–43.1) |
| Maryland            | 512  | 50.6 (45.2–56.0) |
| Massachusetts       | 896  | 42.2 (37.8–46.8) |
| Michigan            | 479  | 37.4 (32.0–43.1) |
| Minnesota           | 279  | 35.4 (29.5–41.7) |
| Mississippi         | 552  | 39.8 (35.1–44.6) |
| Missouri            | 282  | 31.1 (24.5–38.6) |
| Montana             | 465  | 41.5 (36.1–47.2) |
| Nebraska            | 779  | 24.1 (19.6–29.2) |
| Nevada              | 255  | 45.6 (36.7–54.7) |
| New Hampshire        | 352  | 37.4 (32.4–42.7) |
| New Jersey          | 644  | 39.2 (34.6–44.0) |
| New Mexico          | 502  | 43.7 (38.5–49.1) |
| New York            | 381  | 40.4 (34.4–46.7) |

Abbreviation: HIV, Human immunodeficiency virus; CI, confidence interval.

*Age-standardized to the age distribution of cancer survivors in the Behavioral Risk Factor Surveillance System, 2009.*

(continued on next page)
Table 2. Age-Standardized Proportion of HIV Tests Among Cancer Survivors Aged 18 to 64 Years, by State, Behavioral Risk Factor Surveillance System, 2009

| State          | N   | % (95% CI)          |
|----------------|-----|---------------------|
| North Carolina | 745 | 45.7 (41.4–50.1)    |
| North Dakota   | 232 | 29.6 (23.6–36.4)    |
| Ohio           | 525 | 30.0 (25.2–35.3)    |
| Oklahoma       | 466 | 38.8 (34.3–43.5)    |
| Oregon         | 306 | 40.5 (35.0–46.3)    |
| Pennsylvania   | 475 | 34.2 (28.9–39.9)    |
| Rhode Island   | 362 | 31.6 (26.2–37.6)    |
| South Carolina | 586 | 37.5 (32.1–43.3)    |
| South Dakota   | 343 | 25.1 (19.6–31.4)    |
| Tennessee      | 284 | 45.7 (38.6–53.0)    |
| Texas          | 609 | 46.7 (40.6–52.8)    |
| Utah           | 537 | 29.1 (24.7–33.9)    |
| Vermont        | 417 | 39.7 (34.7–45.0)    |
| Virginia       | 286 | 47.9 (41.5–54.4)    |
| Washington     | 1,317 | 44.3 (41.0–47.7)  |
| West Virginia  | 271 | 27.9 (22.8–33.5)    |
| Wisconsin      | 250 | 29.2 (22.3–37.2)    |
| Wyoming        | 404 | 38.0 (32.7–43.5)    |

Abbreviation: HIV, Human immunodeficiency virus; CI, confidence interval.

* Age-standardized to the age distribution of cancer survivors in the Behavioral Risk Factor Surveillance System, 2009.
### Table 3. Model-Adjusted Percentage of HIV Testing by Demographic and Health-Related Characteristics Among US Cancer Survivors Aged 18 to 64 Years, Behavioral Risk Factor Surveillance System, 2009

| Characteristics                  | % (95% CI)       | P Value<sup>a</sup> |
|----------------------------------|------------------|---------------------|
| **Sex**                          | NA               | <.001               |
| Type of cancer                   |                  |                     |
| Male, AIDS-related cancer        | 34.2 (16.6–57.5) | <.001               |
| Male, Non-AIDS–related cancer    | 44.4 (42.2–46.6) |                     |
| Female, AIDS-related cancer      | 48.8 (45.4–52.1) |                     |
| Female, Non-AIDS–related cancer  | 36.2 (34.6–37.7) |                     |
| **Race/ethnicity**               |                  |                     |
| Non-Hispanic white               | 38.3 (37.0–39.5) |                     |
| Non-Hispanic black               | 55.5 (49.9–60.9) | <.001               |
| Hispanic                         | 53.3 (46.6–59.9) |                     |
| Non-Hispanic other               | 45.9 (37.7–54.4) |                     |
| **Age, y**                       |                  | <.001               |
| Education                        |                  |                     |
| <High school graduate            | 36.9 (32.6–41.4) |                     |
| High school graduate             | 33.3 (31.1–35.7) | <.001               |
| Some college                     | 43.1 (40.8–45.3) |                     |
| College graduate                 | 43.6 (41.7–45.5) |                     |
| **Employment**                   |                  | .18                 |
| Employed                         | 39.9 (38.3–41.5) |                     |
| Not employed                     | 41.7 (39.7–43.7) |                     |
| **Marital status**               |                  | <.001               |
| Married or living together       | 37.4 (35.9–38.9) |                     |
| Divorced, separated, or widowed  | 50.6 (48.2–53.0) | <.001               |
| Never married                    | 46.2 (41.7–50.7) |                     |
| **Time since cancer diagnosis, y**|                  | .07                 |
| Nonlinear                        |                  |                     |
| Emotional support                |                  |                     |
| Always                           | 40.5 (39.1–41.9) | .23                 |
| Sometime                         | 42.6 (39.1–46.1) |                     |
| Rare or none                     | 38.1 (34.0–42.5) |                     |
| **Life satisfaction**            |                  | .31                 |
| Very satisfied                   | 40.0 (38.0–42.0) |                     |
| Satisfied                        | 40.5 (38.8–42.3) |                     |
| Dissatisfied                     | 44.1 (39.5–48.7) |                     |

Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.

<sup>a</sup> P value was calculated by using the Wald F test.

<sup>b</sup> Sex by type of cancer interaction term is included in the model (P = .06). P values are calculated from the simultaneous test so that the main effect and interaction coefficients are both equal to zero.
Table 3. Model-Adjusted Percentage of HIV Testing by Demographic and Health-Related Characteristics Among US Cancer Survivors Aged 18 to 64 Years, Behavioral Risk Factor Surveillance System, 2009

| Characteristics                  | % (95% CI)     | P Value<sup>a</sup> |
|----------------------------------|----------------|---------------------|
| Very dissatisfied                | 45.6 (37.8–53.6) |                     |
| **Health insurance**             |                |                     |
| Yes                              | 40.7 (39.4–42.1) | .63                 |
| No                               | 39.7 (36.0–43.6) |                     |
| **Time since last checkup**      |                |                     |
| Within past year                 | 41.4 (40.0–42.8) |                     |
| 1 – <2 y                         | 38.2 (35.0–41.5) | .20                 |
| 2 – <5 y                         | 39.1 (34.8–43.6) |                     |
| ≥5 y                             | 36.8 (31.5–42.4) |                     |
| Never                            | 44.5 (33.4–56.3) |                     |
| **Medical cost concern**         |                |                     |
| Yes                              | 44.5 (41.4–47.8) | .007                |
| No                               | 39.8 (38.4–41.2) |                     |
| **Ever had disability**          |                |                     |
| Yes                              | 47.6 (45.3–49.9) | <.001               |
| No                               | 37.2 (35.7–38.8) |                     |
| **HIV risk behaviors**           |                |                     |
| Yes                              | 47.3 (39.7–55.0) | .08                 |
| No                               | 40.4 (39.1–41.7) |                     |

Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.

<sup>a</sup> P value was calculated by using the Wald F test.

<sup>b</sup> Sex by type of cancer interaction term is included in the model (P = .06). P values are calculated from the simultaneous test so that the main effect and interaction coefficients are both equal to zero.